Mail

JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD

144.77

+0.12 (+0.08%)

As of 12:49PM EST. Market open.

Stock chart is not supported by your current browser

Previous Close	144.65
Open	145.35
Bid	144.88 x 900
Ask	144.91 x 800
Day's Range	144.18 - 146.22
52 Week Range	126.10 - 154.50
Volume	3,464,362
Avg. Volume	6,597,875

Market Cap	381.428B
Beta (5Y Monthly)	0.71
PE Ratio (TTM)	25.71
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	3.80 (2.60%)
Ex-Dividend Date	Feb 23, 2020
1y Target Est	N/A

All

News

Press Releases

PR Newswire
Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline Study. The study is designed to explore if the Heartline Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline Study, individuals must be age 65 or older, a U.S. resident, have Original (traditional) Medicare, own an iPhone 6s or a later model, and agree to provide access to their Medicare claims data. To learn more, determine eligibility to participate, and download the app, visit Heartline.com.
PR Newswire
Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments
Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2 (also known as 2019-nCoV). This latest collaboration will enhance Janssen's ongoing work with global partners to screen a library of existing antiviral molecules, with the aim of identifying compounds with promising antiviral activity against SARS-CoV-2.
PR Newswire
Johnson & Johnson to Participate in the 9th Annual SVB Leerink Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26th, at Lotte New York Palace, NY. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 2:00 p.m. (Eastern Time).
PR Newswire
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services.
PR Newswire
Johnson & Johnson Hit with $750M Punitive Damages Verdict for Failing to Warn about Cancer-Causing Asbestos in Talc Products
A New Jersey jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $750 million in punitive damages to four cancer victims who charged that the company's iconic Johnson's Baby Powder contained cancer-causing asbestos.
PR Newswire
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
Johnson & Johnson (NYSE: JNJ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.
PR Newswire
Dr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of Science
Nominations are now being accepted for the 2020 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates dedicated researchers and champions of science whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 29, 2020, at www.pauljanssenaward.com for consideration by an independent selection committee of world-renowned scientists. The winning scientist(s) will be announced in spring 2020 and receive a $200,000 cash prize.
PR Newswire
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2020 of $0.95 per share on the company's common stock. The dividend is payable on March 10, 2020 to shareholders of record at the close of business on February 25, 2020. The ex-dividend date is February 24, 2020.
PR Newswire
Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced today the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for $750 million. Should Janssen pursue bermekimab indications outside of dermatology, XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. Janssen Research & Development, LLC will develop bermekimab. The agreement was executed through Janssen Biotech, Inc. The transaction will be accounted for as a business combination.
PR Newswire
Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.
Dedicated to shaping the next frontier of surgery, Johnson & Johnsoni (NYSE: JNJ) today announced an agreement to acquire the remaining stake in Verb Surgical Inc. following a successful strategic collaboration with Verily, an Alphabet company. Verb Surgical's world-class robotics and data science capabilities combined with Johnson & Johnson's health care leadership and global reach advance the company's vision to make medical interventions smarter, less invasive and more personalized.
PR Newswire
Johnson & Johnson to Participate in 38th Annual JP Morgan Health Care Conference
Johnson & Johnson (NYSE: JNJ) will participate in the 38th Annual JP Morgan Health Care Conference on Monday, January 13, at the Westin St. Francis in San Francisco. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices and Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 2:30 p.m. (Pacific Time)/5:30 p.m. (Eastern Time). A subsequent Question & Answer session is scheduled for 3:00 p.m. (Pacific Time)/6:00 p.m. (Eastern Time).
PR Newswire
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Alex Gorsky, Chairman and Chief Executive Officer; Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call.
PR Newswire
Johnson & Johnson Announces Commitment to Support Republic of Rwanda's Preparedness Against Ebola Outbreak
Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will provide up to 200,000 Ebola vaccine regimens to the Republic of Rwanda. This commitment will support a new immunization program led by the Rwanda Government that aims to help protect the country's citizens from the Ebola outbreak in neighboring Democratic Republic of the Congo (DRC). The first batches of Janssen vaccine have been delivered to the country, and further shipments are being organized.
PR Newswire
/C O R R E C T I O N -- Johnson & Johnson/
Johnson & Johnson (NYSE: JNJ) announced today that Hubert Joly, Executive Chairman of Best Buy Co., Inc, and Mark A. Weinberger, Former EY Global Chairman and CEO, have been appointed to its Board of Directors.
PR Newswire
Company Investigation Confirms No Asbestos in Johnson's Baby Powder
Johnson & Johnson Consumer Inc. (NYSE: JNJ) (the Company) today reaffirmed that its Johnson's Baby Powder is safe and free of asbestos after a comprehensive investigation into the United States Food and Drug Administration's (FDA) earlier reported finding of sub-trace levels of asbestos (no greater than 0.00002%) in samples from a single bottle of Johnson's Baby Powder.
PR Newswire
Johnson & Johnson Consumer Inc. To Voluntarily Recall A Single Lot Of Johnson's Baby Powder In The United States
NEW BRUNSWICK, N.J., Oct. 18, 2019 /PRNewswire/ -- Out of an abundance of caution, Johnson & Johnson Consumer Inc. (JJCI) announced that it is initiating a voluntary recall in the United States of a single lot of its Johnson's Baby Powder in response to a U.S. Food and Drug Administration (FDA) test indicating the presence of sub-trace levels of chrysotile asbestos contamination (no greater than 0.00002%) in samples from a single bottle purchased from an online retailer. In parallel, JJCI has immediately initiated a rigorous, thorough investigation into this matter, and is working with the FDA to determine the integrity of the tested sample, and the validity of the test results.
PR Newswire
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2019
NEW BRUNSWICK, N.J., Oct. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable on December 10, 2019 to shareholders of record at the close of business on November 26, 2019. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
PR Newswire
Johnson & Johnson Reports 2019 Third-Quarter Results
- Sales of $20.7 billion reflecting growth of 1.9%, operational growth of 3.2%* and adjusted operational growth of 5.2%* - EPS of $1.81 increased 25.7%; adjusted EPS of $2.12 increased 3.4%* - Company ...
ACCESSWIRE
Johnson & Johnson to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 15, 2019 / Johnson & Johnson (NYSE: JNJ ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 15, 2019 at 8:30 AM Eastern ...
PR Newswire
Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review
NEW BRUNSWICK, N.J., Oct. 7, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review (Impact Review), which demonstrates how a strategic Diversity & Inclusion (D&I) philosophy has been a key driver of innovation and impactful business outcomes since its founding more than 130 years ago. Through collaborative achievements and personal stories, the Impact Review explores how the collective wisdom and commitment to inclusion of the 135,000 Johnson & Johnson employees power the company's spirit, and serve patients, customers, and consumers every day. "We believe that only when our employees can be their true, authentic selves can they spark innovative solutions to the problems facing our world," said Peter Fasolo, Ph.D., Executive Vice President, Chief Human Resources Officer, Johnson & Johnson.
PR Newswire
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
NEW BRUNSWICK, N.J., Oct. 4, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and tuberculosis (TB) by 2030. As one of the world's largest healthcare companies, Johnson & Johnson is deeply engaged in global health innovation, working closely with governments and strategic partners to improve the health and well-being of more people in more places around the world. Building on a strong track record set by its Janssen Pharmaceutical Companies in the areas of HIV and TB and Johnson & Johnson's existing Health for Humanity 2020 Goals, Johnson & Johnson will dedicate a team of world-class researchers who will leverage our scientific resources to accelerate the discovery, development and delivery of next generation medicines and vaccines to complement investments being made by governments.
PR Newswire
Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial
NEW BRUNSWICK, N.J., Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admission of liability and removes the Company from the federal trial scheduled to begin October 21, 2019. As part of the agreement, the Company will make a combined $10 million settlement payment to the counties. The settlement allows the Company to avoid the resource demands and uncertainty of a trial as it continues to seek meaningful progress in addressing the nation's opioid crisis.
PR Newswire
California Jury Returns $40 Million Talc Verdict Against Johnson & Johnson
LOS ANGELES, Sept. 30, 2019 /PRNewswire/ -- A California woman suffering from mesothelioma has prevailed in the latest talc trial against Johnson & Johnson, following six days of jury deliberation that ended Friday when the jury awarded her $40 million in damages. Nancy Cabibi, 71, of Hasuer, Idaho, and her husband Phil sued Johnson & Johnson (JNJ), makers of Johnson's Baby Powder, following her pleural mesothelioma diagnosis in 2017. Testing of her body tissue showed the presence of tremolite and anthophyllite asbestos, known contaminants of Johnson's Baby Powder and Shower to Shower, both of which were manufactured by Johnson & Johnson and both of which Mrs. Cabibi used.
PR Newswire
Johnson & Johnson Vision Care, Inc. Introduces ACUVUE™ RevitaLens Multi-Purpose Disinfecting Solution, the Brand's First Contact Lens Solution
ACUVUE™ RevitaLens MPDS Delivers Exceptional Contact Lens Disinfection and All-Day Comfort JACKSONVILLE, Fla. , Sept. 30, 2019 /PRNewswire/ -- Johnson & Johnson Vision † is excited to unveil the first-ever ...
PR Newswire
Johnson & Johnson to Host Investor Conference Call on Third Quarter Results
The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.